Abstract: A single-layer or multilayer film formed from one or more polymeric materials has CIE colour values a* and b* such that ?7?a*?0, ?15?b*?0 and an optical transmission T such that 60%?T?95%. The inventive transparent films provide discoloration compensation that alleviates yellowing caused by UV light.

Abstract: A single-layer or multilayer film formed from one or more polymeric materials has CIE colour values a* and b* such that ?7?a*?0, ?15?b*?0 and an optical transmission T such that 60%?T?95%. The inventive transparent films provide discoloration compensation that alleviates yellowing caused by UV light.

Abstract: A single-layer or multilayer film formed from one or more polymeric materials has CIE colour values a* and b* such that ?7?a*?0, ?15?b*?0 and an optical transmission T such that 60%?T?95%. The inventive transparent films provide discoloration compensation that alleviates yellowing caused by UV light.

Abstract: A single-layer or multilayer film formed from one or more polymeric materials has CIE colour values a* and b* such that ?7?a*?0, ?15?b*?0 and an optical transmission T such that 60%?T?95%. The inventive, transparent films provide discoloration compensation that alleviates yellowing caused by UV light.

Abstract: Implementations relate to a method for establishing an end-to-end encrypted data communication link between a portable medical apparatus and a data-management device. The method comprises at least the following steps: out-of-band transmission of a public key from the medical apparatus to the data-management device, wherein the transmission does not take place via Bluetooth; setting up an encrypted Bluetooth data communication link between the medical apparatus and the data-management device; transmitting a public key from the data-management device to the medical apparatus via the Bluetooth link that has been set up; calculating a combined key on the data-management device and on the medical apparatus; setting up an end-to-end encrypted link between the medical apparatus and the data-management device using the combined key, such as a symmetrical, key.

Abstract: A single-layer or multilayer film formed from one or more polymeric materials has CIE colour values a* and b* such that ?7?a*?0, ?15?b*?0 and an optical transmission T such that 60%?T?95%. The inventive, transparent films provide discoloration compensation that alleviates yellowing caused by UV light.

Abstract: Compounds of the formula (I) in the form of a mixture of predominantly one diastereomer or in the form of pure diastereomers, Z1-Q-P*R0R1??(I), wherein: Z1 is a C-bonded, secondary phosphine group of the formula —P(R)2, wherein R is a hydrocarbon radical or O-atom(s)-containing heterohydrocarbon radical having 1 to 18 carbon atoms and optionally substituted by C1-C6-alkyl, trifluoromethyl, C1-C6-alkoxy, trifluoromethoxy, (C1-C4-alkyl)2amino, (C6H5)3Si, (C1-C12-alkyl)3Si or halogen; Q is selected from the group consisting of: (i) an optionally substituted achiral aromatic group, wherein the achiral aromatic group is bonded directly to Z1 through a carbon atom of the achiral aromatic group and bonded directly to P*R0R1 through a carbon atom of the achiral aromatic group, and (ii) an optionally substituted C1-C4-alkylene group; P* is a chiral phosphorus atom; R0 is methyl; and R1 is a C-bonded optically enriched or optically pure chiral, mono- or polycyclic, nonaromatic hydrocarbon ring; and preparat

Abstract: Compounds of the formula (I) in the form of a mixture of predominantly one diastereomer or in the form of pure diastereomers, Z1-Q-P*R0R1??(I), wherein: Z1 is a C-bonded, secondary phosphine group of the formula —P(R)2, wherein R is a hydrocarbon radical or O-atom(s)-containing heterohydrocarbon radical having 1 to 18 carbon atoms and optionally substituted by C1-C6-alkyl, trifluoromethyl, C1-C6-alkoxy, trifluoromethoxy, (C1-C4-alkyl)2-amino, (C6H5)3Si, (C1-C12-alkyl)3Si or halogen; Q is selected from the group consisting of: (i) an optionally substituted achiral aromatic group, wherein the achiral aromatic group is bonded directly to Z1 through a carbon atom of the achiral aromatic group and bonded directly to P*R0R1 through a carbon atom of the achiral aromatic group, and (ii) an optionally substituted C1-C4-alkylene group; P* is a chiral phosphorus atom; R0 is methyl; and R1 is a C-bonded optically enriched or optically pure chiral, mono- or polycyclic, nonaromatic hydrocarbon ring; and prepar

Abstract: Compounds of the formula (I), in the form of mixtures comprising predominantly one diastereomer or in the form of pure diastereomers, Z1-Q-P*R0R1 (I) in which Z1 is a C-bonded, secondary phosphine group —P(R)2; in which R is in each case independently hydrocarbon radicals or heterohydrocarbon radicals, or Z1 is the —P*R0R1 group; Q is a bivalent, achiral, aromatic base skeleton, a bivalent, achiral ferrocene base skeleton, an optionally substituted bivalent cycloalkane or heterocycloalkane skeleton, or a C1-C4-alkylene skeleton.

Abstract: The present invention refers to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to III, preferably to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to IV, more preferably to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to V, for use as medicaments for the treatment of a disorder connected to reduced neurotransmission, as well as to dietary and pharmaceutical compositions and their uses.

Abstract: Process for preparing ligands of the formula (1), in which R1 is C1-C8-alkyl, unsubstituted cyclopentyl, cyclohexyl, norbornyl or adamantyl, or cyclopentyl or cyclohexyl, substituted by 1 to 3 C1-C4-alkyl or C1-C4-alkoxy, or benzyl, phenyl, naphthyl and anthryl which are unsubstituted or substituted by 1 to 3 C1-C4-alkyl, C1-C4-alkoxy, C1-C4-fluoroalkyl or C1-C4-fluoroalkoxy, F and Cl, each of R2 and R3 is independently a C-bonded hydrocarbon radical or a heterohydrocarbon radical, and R4 is C1-C4-alkyl, cyclopentyl, cyclohexyl, phenyl, methylphenyl, methylbenzyl or benzyl, which comprises (a) stereoselective metallation in ortho position to the amine side-chain of a compound of formula (A) in which R4 is as defined above, reaction with a dihalide of formula R1—PX2 in which R1 is as defined above and X is Cl or Br, stereoselective hydrolysis to give a compound containing an SPO group, and reaction with a secondary phosphine of formula H—PR2R3 in which R2 and R3 are as defined above, to give the compounds of f

Abstract: Compounds of the formula (I), in the form of mixtures comprising predominantly one diastereomer or in the form of pure diastereomers, Z1-Q-P*R0R1 (I) in which Z1 is a C-bonded, secondary phosphine group —P(R)2; in which R is in each case independently hydrocarbon radicals or heterohydrocarbon radicals, or Z1 is the —P*R0R1 group; Q is a bivalent, achiral, aromatic base skeleton, a bivalent, achiral ferrocene base skeleton, an optionally substituted bivalent cycloalkane or heterocycloalkane skeleton, or a C1-C4-alkylene skeleton, and in which base skeletons a secondary phosphine group Z1 is bonded directly to a carbon atom, or, in the case of cyclic base skeletons, directly to a carbon atom or via a C1-C4-alkylene group, and in which base skeletons a P-chiral group —P*R0R1 is bonded directly to a carbon atom, or, in the case of cyclic base skeletons, directly to a carbon atom or via a C1-C4-alkylene group to a carbon atom such that the phosphorus atoms are linked via 1 to 7 atoms of a carbon chain optionally i

Abstract: The invention relates to a novel nutraceutical composition containing Zanthoxlyum bungeanum whole-fruit extract as active ingredient. The term “nutraceutical” as used herein denotes usefulness in nutritional, pharmaceutical and veterinary fields of application. The compositions are useful for improvement of cognitive functions, such as learning, memory and alertness, psychotic stability and maintenance.

Abstract: The invention relates to a novel nutraceutical composition containing Stevia extract or its constituents, such as steviol and stevioside, as active ingredient(s). The term “nutraceutical” as used herein denotes usefulness in nutritional, pharmaceutical and veterinary fields of application. The compositions are useful for improvement of cognitive functions, such as learning, memory and alertness, and psychotic stability.

Abstract: The present invention refers to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to III, preferably to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to IV, more preferably to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to V, for use as medicaments for the treatment of a disorder connected to reduced neurotransmission, as well as to dietary and pharmaceutical compositions and their uses.

Abstract: The invention relates to a novel nutraceutical composition containing thymol and/or p-cymene, or a plant extract containing thymol or p-cymene as active ingredient(s). The compositions are useful for improvement of cognitive functions and psycho-social status, such as learning, memory and alertness, psychotic stability and maintenance.

Abstract: The invention relates to a novel nutraceutical composition containing at least one tripeptide as active ingredient. The term “nutraceutical' as used herein denotes a usefulness in both the nutritional and pharmaceutical field of application. Thus, the novel nutraceutical compositions can find use as supplement to food and beverages, and as pharmaceutical formulations for enteral or parenteral application which may be solid formulations such as capsules or tablets, or liquid formulations, such as solutions or suspensions. As will he evident from the foregoing, the term nutraceutical composition also comprises food and beverages containing the above-specified active ingredients, for example protein hydrolysates which are rich in tripeptides according to the invention.

Abstract: ?-Cryptoxanthin and esters thereof may find use for promoting an increased protein formation and/or prevention of loss of proteins in humans and animals.

Abstract: Nucleic acid sequences coding for a protein having ?,?-carotene 15,15?-monooxygenase activity and their uses in diagnostics, the synthesis of vitamin A and methods for the introduction of the ?,?-carotene 15,15?-monooxygenase cDNA into host cells are disclosed.

Abstract: Nucleic acid sequences coding for a protein having ?,?-carotene 15,15? enzyme activity and their uses in diagnostics, the synthesis of vitamin A and methods for the introduction of the ?,?-carotene 15,15? enzyme cDNA into host cells are disclosed.